Factrel
(Gonadorelin)ApprovedSmall molecule
FerringFactrel is one of 91 small molecule programs targeting Adolescent. It is currently in Approved.
4
Indications
4
Total Trials
2
Active Trials
90
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Polycystic Ovary Syndrome
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Victoza
Novo NordiskApproved
Ozempic
Novo NordiskApproved
Avandia
Jazz PharmaceuticalsApproved
Daliresp
AstraZenecaApproved
Myrbetriq
AstellasApproved
Meridia
AAbbott
Approved
Gynorest
SSolvay Pharmaceuticals
Approved
Tradjenta
Boehringer IngelheimApproved
Andriol
AAuxilium
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Postmenopausal Women1 trial
Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
Active, not recruiting·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 1·NCT04037605·5 enrolled
Polycystic Ovary Syndrome1 trial
Regulatory
FDA Approval Timeline[4]
Sep 30, 1982
FACTREL
NDA NDA018123
Oct 10, 1989
LUTREPULSE KIT
NDA NDA019687
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gonadorelin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]